Benzinga · Jul 31, 2026
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45
Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and lowers the price target from $47 to $45.
DY
NASDAQ · DYN
Dyne Therapeutics, Inc.
Healthcare · Biotechnology
$26.10
Up+$0.12 (+0.46%)
Updated Aug 22, 2026, 3:15 AM
SID Score
6.2/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.77B
- P/E ratio
- -5.35
- Dividend yield
- 0.00%
- 52-week range
- $14.96 – $27.31
- Volume
- 1.18M
- Avg. volume
- 2.94M
Price performance
DYN price history
1M range · 21 trading sessions · Daily adjusted prices
DYN closed at $26.10 after 21 trading sessions, up 6.79% for the selected period.
- Last close
- $26.10
- Period change
- +6.79%
- Period low
- $24.44
- Period high
- $26.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $26.215 | $26.87 | $26.02 | $26.10 | 1.18M |
| Aug 20, 2026 | $26.33 | $26.43 | $25.675 | $25.98 | 1.48M |
| Aug 19, 2026 | $26.50 | $26.94 | $25.98 | $26.78 | 1.95M |
| Aug 18, 2026 | $25.875 | $26.31 | $25.46 | $26.00 | 1.9M |
| Aug 17, 2026 | $25.8978 | $26.43 | $25.30 | $26.15 | 1.32M |
| Aug 14, 2026 | $25.73 | $25.93 | $25.30 | $25.70 | 1.68M |
| Aug 13, 2026 | $26.00 | $26.48 | $25.875 | $25.96 | 1.9M |
| Aug 12, 2026 | $26.84 | $27.305 | $26.11 | $26.17 | 1.78M |
| Aug 11, 2026 | $26.87 | $27.1335 | $26.14 | $26.71 | 1.4M |
| Aug 10, 2026 | $25.78 | $26.84 | $25.70 | $26.50 | 3.02M |
| Aug 7, 2026 | $26.20 | $26.335 | $25.245 | $26.25 | 1.99M |
| Aug 6, 2026 | $26.51 | $26.77 | $25.58 | $25.88 | 1.33M |
| Aug 5, 2026 | $26.325 | $27.09 | $25.86 | $26.17 | 2.15M |
| Aug 4, 2026 | $25.80 | $26.08 | $25.20 | $25.97 | 2.77M |
| Aug 3, 2026 | $25.04 | $25.38 | $24.18 | $25.24 | 2.13M |
| Jul 31, 2026 | $25.80 | $25.99 | $24.41 | $25.18 | 1.83M |
| Jul 30, 2026 | $24.50 | $25.80 | $23.9501 | $25.73 | 1.93M |
| Jul 29, 2026 | $25.96 | $26.09 | $24.71 | $25.10 | 2.11M |
| Jul 28, 2026 | $25.42 | $26.26 | $25.18 | $25.90 | 2.33M |
| Jul 27, 2026 | $25.00 | $26.12 | $24.59 | $25.63 | 3.33M |
| Jul 24, 2026 | $23.92 | $24.87 | $23.70 | $24.44 | 5.07M |
Latest DYN news
The latest Smart Investors Daily articles mentioning DYN.
Stock researchCompany · Overview
DYN research
Overview
Company profile and research snapshot.
Company profile
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $38.11
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | Morgan Stanley | Overweight | — |
| Jul 30, 2026 | RBC Capital | Outperform | — |
| Jul 23, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 26, 2026 | TD Cowen | Buy | — |
| May 15, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 30, 2026
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35
RBC Capital analyst Luca Issi maintains Dyne Therapeutics (NASDAQ:DYN) with a Outperform and raises the price target from $30 to $35.
Benzinga · Jul 29, 2026
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of $(0.97) per share from
Benzinga · Jul 23, 2026
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Eric Schmidt initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
